Literature DB >> 455571

High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

M De Lena, C Brambilla, P Valagussa, G Bonadonna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 455571     DOI： 10.1007/bf00258291

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  16 in total

1.  Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.

Authors:  F Pannuti; A Martoni; E Pollutri; P Camera; F Losinno; H Giusti
Journal:  Panminerva Med       Date:  1976 Mar-Apr       Impact factor: 5.197

2.  Norethisterone acetate in the treatment of advanced breast cancer.

Authors:  R D Rubens; R K Knight; J L Hayward
Journal:  Eur J Cancer       Date:  1976-07       Impact factor: 9.162

3.  Treatment of breast cancer with medroxyprogesterone acetate.

Authors:  F M Muggia; P A Cassieth; M Ochoa; F A Flatow; A Gellhorn; G A Hyman
Journal:  Ann Intern Med       Date:  1968-02       Impact factor: 25.391

4.  A clinical trial of megestrol acetate in advanced breast cancer.

Authors:  F J Ansfield; H L Davis; R A Ellerby; G Ramirez
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

5.  Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.

Authors:  I S Goldenberg
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

6.  Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion.

Authors:  A Segaloff; M Cuningham; B F Rice; J B Weeth
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

7.  Progestin therapy of breast cancer: comparison of agents.

Authors:  B A Stoll
Journal:  Br Med J       Date:  1967-08-05

8.  Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.

Authors:  D J Klaassen; E F Rapp; W E Hirte
Journal:  Cancer Treat Rep       Date:  1976-03

9.  Norethisterone acetate (SH420) in advanced breast cancer.

Authors:  G A Edelstyn
Journal:  Cancer       Date:  1973-12       Impact factor: 6.860

10.  A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

Authors:  F Pannuti; A Martoni; G R Lenaz; E Piana; P Nanni
Journal:  Cancer Treat Rep       Date:  1978-04
View more
  16 in total

1.  A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

Authors:  H L Parnes; J S Abrams; N S Tchekmedyian; N Tait; J Aisner
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

2.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

3.  Inhibition by medroxyprogesterone acetate of precancerous mammary hyperplastic alveolar nodule formation in mice.

Authors:  H Nagasawa; M Fujii; K Hagiwara
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 4.  Current status of high dose progestin treatment in advanced breast cancer.

Authors:  W Mattsson
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.

Authors:  W Scheithauer; C Zielinksi; H Ludwig
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

6.  Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; J J Pratt; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; E van der Ploeg; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Authors:  M Salimtschik; H T Mouridsen; J Loeber; E Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  [High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].

Authors:  H E Wander; C Blossey; J Köbberling; G A Nagel
Journal:  Klin Wochenschr       Date:  1983-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.